Skip to main content
. 2019 Sep 9;16(5):1092–1103. doi: 10.5114/aoms.2019.86101

Table II.

Main characteristics of the included studies

Author, year [ref.] Country Sample number (male/female) Lymph node metastasis (positive/negative) Tumor stage (I/II/III/IV) Detection method TILs phenotype TILs location Cut-off for overexpression Follow-up [months] Median (range) Outcome
Grogg 2003 [14] America 110 (72/38) 29/81 15/15/43/37 HE TIL IT Median 1–131 OS
Lee 2008 [15] Korea 220 (156/164) 165/55 67/53/55/45 IHC CD3, CD8 IT 75th percentile 66.4 (1–108) OS
Perrone 2008 [16] Italy 110 (53/57) 79/31 NA IHC FOXP3 IT Median 36–108 OS, RFS
Haas 2009 [17] Germany 52 (40/12) 28/24 20/19/10/3 IHC FOXP3, CD3, CD8, GrB TS, TP Median 61 (36–132) DFS
Shen 2010 [18] China 135 (90/45) 84/51 40/28/60/7 IHC FOXP3, CD4, CD8 IT Median 57 (5–120) OS
Kashimura 2011 [19] Japan 123 (89/34) 42/81 80/10/13/20 IHC FOXP3 IT Median 1–108 OS, DFS
Kim HI 2011 [20] Korea 180 (126/54) 107/73 0/81/99/0 IHC CD3, CD4, CD8 FOXP3, GrB IT Median 45 OS
Wang 2011 [21] China 107 (69/38) 69/38 NA IHC FOXP3 IT, PT Median 62 (2–120) OS
Chen 2012 [22] China 152 (117/35) 98/35 10/31/93/18 HE TIL TN 19.05/HPF 12–144 OS, DFS
Kim KJ 2013 [23] Korea 99 (55/44) 57/42 Not clear IHC CD8 IT Median and 60th percentile 59 (1–96) OS
Kim JW 2014 [24] Korea 243 (152/91) 124/119 120/41/82/0 IHC CD3, CD4, CD8 IT Median 74 (0–123) OS, DFS
Arigami 2014 [25] Japan 120 (74/46) 66/54 46/16/36/22 IHC CD3 IT Median 36 (1–112) OS
Geng 2014 [26] China 100 (61/39) 68/32 NA ICH FOXP3 IT 25.0 % field > 60 OS
Liu 2015 [27] China 166 (125/41) 118/48 23/41/80/22 IHC CD3, CD4, CD8, FOXP3 IT, PT Median 79.59 (36–96) OS
Kang 2016 [28] Korea 120 (96/24) 33/87 74/26/19/1 HE TIL TS Median 22.2 (2.1–50.8) RFS, DFS
Kawazoe 2016 [29] Japan 487 (327/160) 449/38 0/0/358/129 IHC CD3, CD4, CD8, FOXP3 IT Median NA OS
Kim EK 2016 [30] Korea 396 (270/126) 246/156 165/77/143/11 ICH CD3, FOXP3 IT Mean value 53.9 (0–84.5) OS
Dong 2016 [31] China 100 (72/28) NA 0/36/34/30 ICH CD8 IT Median 36.5 (2–88) OS, DFS

TIL – tumor-infiltrating lymphocyte, PT – peritumoral, IT – intratumoral, TS – tumor stroma, TN – tumor nest, TP – tumor parenchyma, OS – overall survival, DFS – disease-free survival, RFS – relapse-free survival, NA – not available, IHC – immunohistochemistry, HE – hematoxylin-eosin, DFS – disease-free survival.